# Avak Kahvejian

> Avak Kahvejian is a Series B investor at Etiome (Cambridge) backing Biotechnology and Therapeutics. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Etiome](https://shizune.co/investors/profile/etiome)
- Location: Cambridge, United States
- Total investments: 7
- Last investment: Apr 2025
- Lead investor: 71%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/avakk
- X (Twitter): http://twitter.com/AvakK
- Website: https://x.com/avakk
- Facebook: https://www.facebook.com/avak.kahvejian

Avak Kahvejian is a Series B investor at Etiome in Cambridge focused on Biotechnology and Therapeutics. Avak Kahvejian is based out of Cambridge, Massachusetts, and is the General Partner of Flagship Pioneering. Avak previously worked at Sail Biomedicines as a Founding CEO and Board Member. Avak Kahvejian attended McGill University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 57% |
| Therapeutics | 3 | 43% |
| Medical | 2 | 29% |
| Biopharma | 1 | 14% |
| Health Care | 1 | 14% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 43% |
| Series A | 2 | 29% |
| Series C | 1 | 14% |
| Venture - Series Unknown | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Etiome | Etiome is disrupting the progression of disease before it becomes debilitating and irreversible by developing and deploying Biostaged Medicines. | $50M | Series A | Apr 24, 2025 |  |
| Ampersand Biomedicines | Ampersand Biomedicines is an Address, Navigate, Design (AND)™ Platform that develops novel programming therapeutics that are designed to act at the sight of disease. | $65M | Series B | Mar 19, 2025 |  |
| Ring Therapeutics | Ring Therapeutics is a multi-product platform company focused on discovering and developing Anellovector therapeutics to unlock the full potential of gene therapy. Founded by Flagship Pioneering, Ring is pioneering the first redosable and targetable gene therapy platform by harnessing the biology of the human commensal virome. The company isexpanding the applications of gene therapy beyond gene replacement, enabling a much wider array of modalities and mechanisms to treat previously inaccessible diseases. | $86.5M | Series C | Mar 09, 2023 |  |
| Ampersand Biomedicines | Ampersand Biomedicines is an Address, Navigate, Design (AND)™ Platform that develops novel programming therapeutics that are designed to act at the sight of disease. | $50M | Venture - Series Unknown | Mar 07, 2023 |  |
| Laronde | Laronde develops an eRNA-based therapeutic platform that is capable of indicating diverse proteins inside the body. It is persistent, non-immunogenic, allows for repeat dosing, and offers flexibility in formulation and delivery.Laronde was founded in 2017 by Flagship Labs, the innovation foundry of Flagship Pioneering. The company is rapidlyscaling to support the parallel development of multiple programs across many disease areas. | $440M | Series B | Aug 30, 2021 |  |
| Ring Therapeutics | Ring Therapeutics is a multi-product platform company focused on discovering and developing Anellovector therapeutics to unlock the full potential of gene therapy. Founded by Flagship Pioneering, Ring is pioneering the first redosable and targetable gene therapy platform by harnessing the biology of the human commensal virome. The company isexpanding the applications of gene therapy beyond gene replacement, enabling a much wider array of modalities and mechanisms to treat previously inaccessible diseases. | $117M | Series B | Jul 28, 2021 |  |
| Laronde | Laronde develops an eRNA-based therapeutic platform that is capable of indicating diverse proteins inside the body. It is persistent, non-immunogenic, allows for repeat dosing, and offers flexibility in formulation and delivery.Laronde was founded in 2017 by Flagship Labs, the innovation foundry of Flagship Pioneering. The company is rapidlyscaling to support the parallel development of multiple programs across many disease areas. | $50M | Series A | May 10, 2021 |  |

7 of 7 investments shown.

## Co-investors
- [Invus](https://shizune.co/investors/profile/invus) — VC Fund, 3 deals together
- [T. Rowe Price](https://shizune.co/investors/profile/t-rowe-price) — VC Fund, 3 deals together
- [Altitude Life Science Ventures](https://shizune.co/investors/profile/altitude-life-science-ventures) — VC Fund, 2 deals together
- [Partners Investment](https://shizune.co/investors/profile/partners-investment) — VC Fund, 2 deals together
- [UPMC Enterprises](https://shizune.co/investors/profile/upmc-enterprises) — VC Fund, 2 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 1 deal together

## About Etiome

VC Fund · Cambridge, United States

Etiome is disrupting the progression of disease before it becomes debilitating and irreversible by developing and deploying Biostaged Medicines.

2 contacts available at Etiome.

| Name | Title | Profile |
| --- | --- | --- |
| Avak Kahvejian | Founding CEO & Board Member | https://shizune.co/investors/profile/avak-kahvejian |
| Noubar Afeyan | Co-Founder | https://shizune.co/investors/profile/noubar-afeyan |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Avak Kahvejian invest in?

Avak Kahvejian invests primarily in Biotechnology, Therapeutics and Medical startups, most often at Series B and Series A stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Avak Kahvejian last invest?

The most recent investment recorded for Avak Kahvejian closed in Apr 2025. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co